Flagship-backed startup brings in another $86.5M for ring-shaped viruses

Two years ago, Flagship Pioneering spinout Ring Therapeutics laid out a $117 million plan: to fine-tune a class of viruses for genetic medicines, identify a handful of target disease areas and double its headcount in the process. Today, it has done all those things. So the company has raised more money — this time, $86.5 million in a Series C round — to get it to the next step.